Anthony Ike

Dr. Anthony Ike

Department of Microbiology, University of Nigeria, Nsukka
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2020 in VirusDisease
Verified
Journal Article
Closed access
PDF file
COC. D. Ojobor
C. D. Ojobor
COC. V. Olovo
C. V. Olovo
LOL. O. Onah
L. O. Onah
AIAnthony Ike
Anthony Ike

4 January 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
AIAnthony Ike
Anthony Ike
COChukwuebuka Ononugbo
Chukwuebuka Ononugbo
OOOkechukwu Obi
Okechukwu Obi
Chisom Joshua OnuChisom Joshua Onu
Chisom Joshua Onu
COChinasa V. Olovo
Chinasa V. Olovo
OOODINAKACHUKWU OMEKE
ODINAKACHUKWU OMEKE
Infectious bronchitis (IB) and Newcastle disease (ND) are two important diseases of poultry and have remained a threat to the development of the poultry industry in many parts of the world. The immunology of avian has been well studied and numerous vaccines have been developed against the two viruses. Most of these vaccines are either inactivated vaccines or live attenuated vaccines. Inactivated vaccines induce weak cellular immune responses and require priming with live or other types of vaccines. Advanced technology has been used to produce several types of vaccines that can initiate prime immune responses. However, as a result of rapid genetic variations, the control of these two viral infections through vaccination has remained a challenge. Using various strategies such as combination of live attenuated and inactivated vaccines, development of IB/ND vaccines, use of DNA vaccines and transgenic plant vaccines, the problem is being surmounted. It is hoped that with increasing understanding of the immunological mechanisms in birds that are used in fighting these viruses, a more successful control of the diseases will be achieved. This will go a long way in contributing to global food security and the economic development of many developing countries, given the role of poultry in the attainment of these goals.

12 June 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
AIAnthony Ike
Anthony Ike
Chisom Joshua OnuChisom Joshua Onu
Chisom Joshua Onu
COChukwuebuka Ononugbo
Chukwuebuka Ononugbo
EREleazar Reward
Eleazar Reward
Sophia MuoSophia Muo
Sophia Muo
Herpes simplex virus (HSV) infections are among the most common viral infections and usually last for a lifetime. The virus can potentially be controlled with vaccines since humans are the only known host. However, despite the development and trial of many vaccines, this has not yet been possible. This is normally attributed to the high latency potential of the virus. Numerous immune cells, particularly the natural killer cells and interferon gamma and pathways that are used by the body to fight HSV infections have been identified. On the other hand, the virus has developed different mechanisms, including using different microRNAs to inhibit apoptosis and autophagy to avoid clearance and aid latency induction. Both traditional and new methods of vaccine development, including the use of live attenuated vaccines, replication incompetent vaccines, subunit vaccines and recombinant DNA vaccines are now being employed to develop an effective vaccine against the virus. We conclude that this review has contributed to a better understanding of the interplay between the immune system and the virus, which is necessary for the development of an effective vaccine against HSV.

30 September 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
VNVictory Chizaram Nnaemeka
Victory Chizaram Nnaemeka
ROReuben Ogba Onwe
Reuben Ogba Onwe
AEAdaku Lydia Ekwedike
Adaku Lydia Ekwedike
OOOluwakemi Elizabeth Oyedele
Oluwakemi Elizabeth Oyedele
TTThomas Sambo Tsiterimam
Thomas Sambo Tsiterimam
AIAnthony Ike
Anthony Ike
Healthcare workers (HCWs) are regarded as role models regarding health-related issues, including vaccination. Therefore, it is essential to identify the predictors for COVID-19 vaccine acceptance among them. A cross-sectional study to assess the risk perception, attitudes and knowledge of HCWs toward COVID-19 vaccination was carried out. A total of 710 responses were received between September 2021 and March 2022, from HCWs in the Northern, Western and Eastern regions of Nigeria. Cross tabulations were performed to determine statistical relations between sociodemographic variables, knowledge, attitudes and risk perceptions concerning COVID-19 vaccine acceptance. Multinomial logistic regression analysis was performed to determine the predictive variables for COVID-19 vaccine acceptance. Statistical analyses were performed and P-values less than 0.05 were considered statistically significant at a CI of 95%. Results showed that 59.3% of the participants were amenable to COVID-19 vaccines. Multinomial regression analysis identified 14 variables at α < 0.05 as predictors for vaccine acceptance. Male HCWs were 2.8 times more likely to accept the vaccine than their female counterparts. HCWs that were knowledgeable of the different kinds of vaccines, were willing to recommend the vaccines to their patients, believed that the timing of COVID-19 vaccination was appropriate and had recent vaccination history within three years were 1.6, 24.9, 4.4 and 3.1 times more likely to take COVID-19 vaccine than those not sure. The study found a relatively high trust (51.3%) in the Nigerian Center for Disease Control (NCDC) for information regarding COVID-19 vaccines. Therefore, the NDCD should disseminate more robust insights regarding the safety profiles of various COVID-19 vaccines.

24 October 2019 in Pathogens and Global Health
Verified
Journal Article
Closed access
EREleazar E. Reward
Eleazar E. Reward
Sophia MuoSophia Muo
Sophia Muo
IOIbuchukwu N. A. Orabueze
Ibuchukwu N. A. Orabueze
AIAnthony Ike
Anthony Ike
A source of comprehensive information on the prevalence of herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) can help researchers and policymakers address HSV related burden in the society. At the moment, this is not readily available. This study aims to fill this gap by attempting to estimate the seroprevalence of HSV-1 and HSV-2 infections in Nigeria on the basis of published data. A systematic review and meta-analysis including cross-sectional studies on HSV-1 and HSV-2 in Nigeria was conducted. Electronic databases including PubMed/MEDLINE, CENTRAL, African Journals Online (AJOL), ScienceDirect, WHO-Afro Library, WHO-IRIS and African Index Medicus were searched for English Language publications on HSV-1 and HSV-2. Seven relevant publications were identified. Seroprevalence measures of 3 and 23 for HSV-1 and HSV-2, respectively, were extracted. The pooled mean seroprevalences for HSV-1 and HSV-2 were 74.0% (37.4–99.4%) and 63.4% (56.1–70.4%) respectively. The mean seroprevalence of HSV-1 was higher among females, 82.4% (n = 509, CI, 36.6–100.0%), than males, 54.5% (n = 198, CI, 47.6–61.4%). The mean seroprevalence of HSV-2 were 51.8% (n = 1414, CI: 39.4–64.0%) and 86.5% (n = 162, CI: 80.8–91.3%) among healthy and clinical populations, respectively. The study was limited by the paucity of quality studies, variations in diagnostic methods and high heterogeneity in seroprevalence estimates. In conclusion, the seroprevalence of HSV-1 and HSV-2 remain high in Nigeria. Large and representative national epidemiological surveys covering all regions and specific groups are recommended.

16 November 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
Chukwuemeka Samson AhamefuleChukwuemeka Samson Ahamefule
Chukwuemeka Samson Ahamefule
Blessing C. EzeudujiBlessing C. Ezeuduji
Blessing C. Ezeuduji
JOJames Ogbonna
James Ogbonna
AMAnene N. Moneke
Anene N. Moneke
AIAnthony Ike
Anthony Ike
WFWenxia Fang
Wenxia Fang
With the mortality rate of invasive aspergillosis caused by Aspergillus fumigatus reaching almost 100% among some groups of patients, and with the rapidly increasing resistance of A. fumigatus to available antifungal drugs, new antifungal agents have never been more desirable than now. Numerous bioactive compounds were isolated and characterized from marine resources. However, only a few exhibited a potent activity against A. fumigatus when compared to the multitude that did against some other pathogens. Here, we review the marine bioactive compounds that display a bioactivity against A. fumigatus. The challenges hampering the discovery of antifungal agents from this rich habitat are also critically analyzed. Further, we propose strategies that could speed up an efficient discovery and broaden the dimensions of screening in order to obtain promising in vivo antifungal agents with new modes of action.